… collections, and 10 retrospective case series were included in this analysis for a total of
3502 patients treated with FOLFIRI-B chemotherapy as first-line treatment. The number of …

… bevacizumab/mFOLFOX‐6. Our results suggest that Ang‐2 is not a relevant therapeutic target
in first‐line … , low Ang‐2 baseline levels correlated with better PFS and OS [15, 16]. These …

… First‐line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such
as bevacizumab (… in STEAM had BRAF‐mutated disease to allow correlation with outcomes. …

… in colorectal cancer [9] and in non-small cell lung cancer [10]. … progression on standard first
line treatment with dacarbazine (… assessed for subsequent correlation with clinical outcome. …

… be markers for favorable clinical outcome, HT development … toxicities during therapy with
bevacizumab and/or sorafenib. … with PFS in patients with colon cancer treated with sorafenib (…

… or sequentially, strongly correlates with median survival in … arterial hypertension, proteinuria,
arterial thrombotic events, … tumors, first-line treatment should include bevacizumab plus …

… increase in toxicity to a significantly higher incidence of arterial hypertension (AHT) [Table
2]. … had a significantly increased risk of GI perforation, with a positive correlation with higher …

… in the treatment of various neoplasms. Based on a significant clinical benefit, bevacizumab
is … and Drug Administration approved for treatment of advanced colorectal cancer (CRC) (in …

… , bevacizumab in combination with XELOX or FOLFOX-4 in the first line treatment of patients
… miRNA in the plasma of patients with cancer and their correlation with the expression in the …

… for the treatment of patients with metastatic colorectal cancer, … or recommended against as
first-line treatment, primarily for … no consistent correlation between HTN and clinical benefit. In …